Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Differentiating disseminated cryptococcosis from pulmonary cryptococcosis: Roles of clinical characteristics and cryptococcal antigen.

Created on 18 Oct 2026

Authors

Xiaolan Zhou, Su Xu, Junhao Zhu, Qiangqiang Zhang, Min Zhu, Minggui Wang

Published in

Emerging microbes & infections. Pages 2751728. Oct 17, 2026. Epub Oct 17, 2026.

Abstract

AbstractDistinguishing disseminated cryptococcosis (DC) from localized pulmonary cryptococcosis (PC) is crucial due to divergent management and disparate prognoses. This study aimed to recognize associated factors for DC from PC in non-human immunodeficiency virus (HIV) patients. Accordingly, 475 pathologically confirmed cryptococcosis cases (391 PC and 84 DC) were retrospectively reviewed over a 20-year period at a tertiary hospital in China. Clinical, radiographic, dynamic serum cryptococcal antigen (CrAg) titer profiles, treatment and prognosis were analyzed. Patients with DC were significantly associated with a history of glucocorticoid therapy (16.7% vs. 5.6%; P = 0.001) and autoimmune diseases (16.7% vs. 6.1%; P = 0.001) compared with PC, aggressive thoracic computed tomography findings, including patchy exudation (P = 0.001) and cavitation (P = 0.009), and markedly higher baseline median serum CrAg titers (1:1280 vs. 1:80, P < 0.001). By multivariable analysis, CNS symptoms (adjusted OR [aOR] 131.12, 95% CI 10.21-1683.9, P = 0.001), chronic liver disease (aOR 15.21, 95% CI 1.06-217.69, P = 0.045), and baseline serum CrAg ≥1:80 (aOR 13.51, 95% CI 1.39-131.07, P = 0.025) remained independently associated with DC. An initial CrAg titer ≥ 1:80 should prompt careful CNS evaluation and consideration of lumbar puncture. Patients with DC had significantly longer median CrAg clearance (P = 0.001) and antifungal duration (18 vs. 6 months), with higher mortality (9.5% vs. 1.0%; P < 0.001) compared to PC. Early risk-stratification is imperative to optimize interventions and improve survival.

PMID:
42891613
Bibliographic data and abstract were imported from PubMed on 18 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 19
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement